Several therapeutics, including small molecules and antibodies, such as foretinib, cabozantinib and YYB-101, have been developed that target the HGF/c-MET pathway and have been tested in clinical trials in ovarian cancer patients, yet none has shown significant efficacy [22]. Here, MET is linked to ovarian carcinoma.